Skip to main content

Table 1 Flow of patients through the study (inclusion criteria)

From: Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment

Genotyped 710
Overlap with women with mammograms retrieved 570
Nonmissing date of initiation of tamoxifen therapy 562
Duration of treatment ≥6 months 530
Complete set of baseline and follow-up mammograms 309
Postmenopausal at baseline 308
Genotyped from blood 278
Baseline percent mammographic density (PMD) ≥10% 186